Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Group 1 - The company HaiTe Bio (300683) responded to investor inquiries on its interactive platform regarding the specific situation of Shaite, directing investors to refer to the company's periodic reports for detailed information [1]

Group 1 - The company, HaiTe Bio (300683), is actively monitoring and valuing the application and development of a specific technology in its research and development efforts [1] - The company will promptly announce any significant matters related to this technology [1]

格隆汇1月23日丨海特生物(300683.SZ)公布，预计2025年亏损17,000万元–24,000万元，扣非亏损20,600 万元–26,800万元，营业收入48,210万元–58,659万元。 1、报告期内，公司原料药及中间体业务，因市场竞争加剧，订单不足，营业收入不达预期，加之相关 固定资产折旧摊销较大，造成原料药及中间体业务持续亏损。因受市场竞争等因素的影响，销售价格降 低,子公司汉瑞药业（荆门）有限公司对存货计提的减值损失约1,193万元。2、报告期内，子公司天津市 汉康医药生物技术有限公司其主要从事药物研发及临床试验相关工作，在市场环境及政策调控等因素 下，公司预计2025年当期营收将面临一定程度的下滑，并由此出现商誉减值迹象。基于谨慎性原则，公 司对收购天津汉康股权形成的商誉计提减值准备8,500万元。3、预计报告期内非经常损益对净利润的影 响额为2,800万元至3,600万元：主要系投资收益和政府补助。4、权益法核算的投资公司西威埃医药技术 （上海）有限公司计提长期股权投资减值1,498.59万元。 ...

证券代码：300683 证券简称：海特生物 公告编号：2026-010 武汉海特生物制药股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 预计净利润为负值。 | 项 目 | 本报告期（2025 | 年 1 月至 | 12 月） | 上年同期（2024 | 年） | | --- | --- | --- | --- | --- | --- | | 利润总额 | 亏损：18,000 | 万元–26,000 | 万元 | 亏损：8014.06 | 万元 | | 归属于上市公司股东的净利润 | 亏损：17,000 | 万元–24,000 | 万元 | 亏损：6,934.87 | 万元 | | 扣除非经常性损益后的净利润 | 亏损：20,600 | 万元–26,800 | 万元 | 亏损：10,372.65 | 万元 | | 营业收入 | 48,210 | 万元–58,659 | 万元 | 64,897.41 | ...

证券代码：300683 证券简称：海特生物 公告编号：2026-011 武汉海特生物制药股份有限公司 本公司以预期信用损失为基础，对应收账款、应收票据、其他应收款进行减 值测试并确认减值损失。经初步测试，2025年度公司拟计提信用减值损失34.90 万元。 关于2025年度拟计提资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假记 载、误导性陈述或者重大遗漏。 一、 本次拟计提资产减值准备情况概述 根据《企业会计准则》及武汉海特生物制药股份有限公司（以下简称"公司"、 "本公司"）会计政策的相关规定，公司合并报表范围内各公司对2025年12月末所 属资产进行了减值测试，基于谨慎性原则，拟对可能发生资产减值损失的相关资 产计提减值准备，预计2025年全年计提资产减值准备金额合计为12,089.99万元， 本次计提资产减值准备情况未经会计师事务所审计。 具体明细如下： 单位：人民币万元 | 项目名称 | 年度拟计提减值准备金额 2025 | | --- | --- | | 1、信用减值损失 | 34.90 | | 其中：应收账款坏账损失 | 48.08 | | 应收票据损失 | ...

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]